An Hsp70 vaccine derived from MC38 cells expressing the tumor antigen MUC1 was shown to trigger DC maturation and expression of costimulatory molecules and trigger CTL that could kill target tumor cells in an antigen- (MUC1-) specific manner [87]. This evidence concerns the gene MUC1 and neoplasm.